Mennini, Francesco Saverio; Gori, Mario; Vlachaki, Ioanna; … - In: Health economics review 11 (2021) 1, pp. 1-10
Background: Vaborem is a fixed dose combination of vaborbactam and meropenem with potent activity against target Carbapenem-resistant Enterobacterales (CRE) pathogens, optimally developed for Klebsiella pneumoniae carbapenemase (KPC). The study aims to evaluate the cost-effectiveness of Vaborem...
